FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:905-914 September 28, 2000 Number 13 Next

	Full Text PDF Editorial by Mayer, R. J. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer. Irinotecan prolongs survival in patients with colorectal cancer that is refractory to treatment with fluorouracil and leucovorin. In a multicenter trial, we compared a combination of irinotecan, fluorouracil, and leucovorin with bolus doses of fluorouracil and leucovorin as first-line therapy for metastatic colorectal cancer. A third group of patients received irinotecan alone.

Methods Patients were randomly assigned to receive irinotecan (125 mg per square meter of body-surface area intravenously), fluorouracil (500 mg per square meter as an intravenous bolus), and leucovorin (20 mg per square meter as an intravenous bolus) weekly for four weeks every six weeks; fluorouracil (425 mg per square meter as an intravenous bolus) and leucovorin (20 mg per square meter as an intravenous bolus) daily for five consecutive days every four weeks; or irinotecan alone (125 mg per square meter intravenously) weekly for four weeks every six weeks. End points included progression-free survival and overall survival.

Results Of 683 patients, 231 were assigned to receive irinotecan, fluorouracil, and leucovorin; 226 to receive fluorouracil and leucovorin; and 226 to receive irinotecan alone. In an intention-to-treat analysis, as compared with treatment with fluorouracil and leucovorin, treatment with irinotecan, fluorouracil, and leucovorin resulted in significantly longer progression-free survival (median, 7.0 vs. 4.3 months; P=0.004), a higher rate of confirmed response (39 percent vs. 21 percent, P<0.001), and longer overall survival (median, 14.8 vs. 12.6 months; P=0.04). Results for irinotecan alone were similar to those for fluorouracil and leucovorin. Grade 3 (severe) diarrhea was more common during treatment with irinotecan, fluorouracil, and leucovorin than during treatment with fluorouracil and leucovorin, but the incidence of grade 4 (life-threatening) diarrhea was similar in the two groups (<8 percent). Grade 3 or 4 mucositis, grade 4 neutropenia, and neutropenic fever were less frequent during treatment with irinotecan, fluorouracil, and leucovorin. Adding irinotecan to the regimen of fluorouracil and leucovorin did not compromise the quality of life.

Conclusions Weekly treatment with irinotecan plus fluorouracil and leucovorin is superior to a widely used regimen of fluorouracil and leucovorin for metastatic colorectal cancer in terms of progression-free survival and overall survival.

Source Information

From Memorial Sloan-Kettering Cancer Center, New York (L.B.S.); U.S. Oncology, Dallas (J.V.C.); the Vanderbilt Cancer Center, Nashville (C.B.); UCLA Medical Center, Los Angeles (L.S.R.); Kaiser Permanente Medical Center, Vallejo, Calif. (L.F.); Princess Margaret Hospital, Toronto (M.J.M.); Ottawa Regional Cancer Center, Ottawa, Ont., Canada (J.A.M.); Newcastle Mater Misericordiae Hospital, Waratah, N.S.W., Australia (S.P.A.); and Pharmacia Corporation, Peapack, N.J. (P.K.L., N.P., G.L.E., L.L.M.).

Address reprint requests to Dr. Saltz at the Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021.

Full Text of this Article

Related Letters:

Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Erlichman C., Goldberg R. M., O'Connell M. J., Vaiani M., Trippoli S., Messori A., Pestalozzi B. C., Pignon J.-P., Ducreux M., Saltz L. B., Miller L. L.
Extract | Full Text | PDF  
N Engl J Med 2001; 344:305-307, Jan 25, 2001. Correspondence

This article has been cited by other articles:

• Meulenbeld, H. J., van Steenbergen, L. N., Janssen-Heijnen, M. L. G., Lemmens, V. E. P. P., Creemers, G. J. (2008). Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004. Ann Oncol 19: 1600-1604 [Abstract] [Full Text]  
• Aranda, E., Valladares, M., Martinez-Villacampa, M., Benavides, M., Gomez, A., Massutti, B., Marcuello, E., Constenla, M., Camara, J. C., Carrato, A., Duenas, R., Reboredo, M., Navarro, M., Diaz-Rubio, E. (2008). Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. Ann Oncol 0: mdn557v1-mdn557 [Abstract] [Full Text]  
• Kaufman, H. L., Lenz, H.-J., Marshall, J., Singh, D., Garett, C., Cripps, C., Moore, M., von Mehren, M., Dalfen, R., Heim, W. J., Conry, R. M., Urba, W. J., Benson, A. B. III, Yu, M., Caterini, J., Kim-Schulze, S., DeBenedette, M., Salha, D., Vogel, T., Elias, I., Berinstein, N. L. (2008). Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer. Clin. Cancer Res. 14: 4843-4849 [Abstract] [Full Text]  
• McKibbin, T., Frei, C. R., Greene, R. E., Kwan, P., Simon, J., Koeller, J. M. (2008). Disparities in the Use of Chemotherapy and Monoclonal Antibody Therapy for Elderly Advanced Colorectal Cancer Patients in the Community Oncology Setting. The Oncologist 13: 876-885 [Abstract] [Full Text]  
• Carethers, J. M. (2008). Review: Systemic treatment of advanced colorectal cancer: Tailoring therapy to the tumor. Therapeutic Advances in Gastroenterology 1: 33-42 [Abstract]  
• Qvortrup, C., Yilmaz, M., Ogreid, D., Berglund, A., Balteskard, L., Ploen, J., Fokstuen, T., Starkhammar, H., Sorbye, H., Tveit, K., Pfeiffer, P. (2008). Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil. Ann Oncol 19: 1154-1159 [Abstract] [Full Text]  
• van Iersel, L. B. J., Gelderblom, H., Vahrmeijer, A. L., van Persijn van Meerten, E. L., Tijl, F. G. J., Putter, H., Hartgrink, H. H., Kuppen, P. J. K., Nortier, J. W. R., Tollenaar, R. A. E. M., van de Velde, C. J. H. (2008). Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. Ann Oncol 19: 1127-1134 [Abstract] [Full Text]  
• Schwartz, R. N. (2008). Management of early and advanced colorectal cancer: Therapeutic issues. Am J Health Syst Pharm 65: S8-S14 [Abstract] [Full Text]  
• Hecht, J. R. (2008). Current and emerging therapies for metastatic colorectal cancer: Applying research findings to clinical practice. Am J Health Syst Pharm 65: S15-S21 [Abstract] [Full Text]  
• O'Connell, M. J., Campbell, M. E., Goldberg, R. M., Grothey, A., Seitz, J.-F., Benedetti, J. K., Andre, T., Haller, D. G., Sargent, D. J. (2008). Survival Following Recurrence in Stage II and III Colon Cancer: Findings From the ACCENT Data Set. JCO 26: 2336-2341 [Abstract] [Full Text]  
• Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., Vega-Villegas, M. E., Eng, C., Steinhauer, E. U., Prausova, J., Lenz, H.-J., Borg, C., Middleton, G., Kroning, H., Luppi, G., Kisker, O., Zubel, A., Langer, C., Kopit, J., Burris, H. A. III (2008). EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer. JCO 26: 2311-2319 [Abstract] [Full Text]  
• Glimelius, B., Sorbye, H., Balteskard, L., Bystrom, P., Pfeiffer, P., Tveit, K., Heikkila, R., Keldsen, N., Albertsson, M., Starkhammar, H., Garmo, H., Berglund, A. (2008). A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Ann Oncol 19: 909-914 [Abstract] [Full Text]  
• Adam, R., Wicherts, D. A., de Haas, R. J., Aloia, T., Levi, F., Paule, B., Guettier, C., Kunstlinger, F., Delvart, V., Azoulay, D., Castaing, D. (2008). Complete Pathologic Response After Preoperative Chemotherapy for Colorectal Liver Metastases: Myth or Reality?. JCO 26: 1635-1641 [Abstract] [Full Text]  
• Kobayashi, H., Sugihara, K., Uetake, H., Higuchi, T., Yasuno, M., Enomoto, M., Kuramochi, H., Lenz, H.-J., Danenberg, K. D., Danenberg, P. V. (2008). Messenger RNA Expression of Vascular Endothelial Growth Factor and Its Receptors in Primary Colorectal Cancer and Corresponding Liver Metastasis. Ann. Surg. Oncol. 15: 1232-1238 [Abstract] [Full Text]  
• Xue, H., Sawyer, M. B., Field, C. J., Dieleman, L. A., Murray, D., Baracos, V. E. (2008). Bolus Oral Glutamine Protects Rats against CPT-11-Induced Diarrhea and Differentially Activates Cytoprotective Mechanisms in Host Intestine but Not Tumor. J. Nutr. 138: 740-746 [Abstract] [Full Text]  
• Kohne, C.-H., Folprecht, G., Goldberg, R. M., Mitry, E., Rougier, P. (2008). Chemotherapy in Elderly Patients with Colorectal Cancer. The Oncologist 13: 390-402 [Abstract] [Full Text]  
• Folprecht, G., Seymour, M. T., Saltz, L., Douillard, J.-Y., Hecker, H., Stephens, R. J., Maughan, T. S., Van Cutsem, E., Rougier, P., Mitry, E., Schubert, U., Kohne, C.-H. (2008). Irinotecan/Fluorouracil Combination in First-Line Therapy of Older and Younger Patients With Metastatic Colorectal Cancer: Combined Analysis of 2,691 Patients in Randomized Controlled Trials. JCO 26: 1443-1451 [Abstract] [Full Text]  
• Sapra, P., Zhao, H., Mehlig, M., Malaby, J., Kraft, P., Longley, C., Greenberger, L. M., Horak, I. D. (2008). Novel Delivery of SN38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11-Refractory Model. Clin. Cancer Res. 14: 1888-1896 [Abstract] [Full Text]  
• Zalcberg, J. R., Rosen, L. S., Abdi, E., Davis, I. D., Gutheil, J., Schnell, F. M., Cesano, A., Gayko, U., Chen, M.-G., Clarke, S. (2008). Role of Palifermin in Fluorouracil-Based Therapy for Metastatic Colorectal Cancer. JCO 26: 1386-1387 [Full Text]  
• Ramsay, E. C., Anantha, M., Zastre, J., Meijs, M., Zonderhuis, J., Strutt, D., Webb, M. S., Waterhouse, D., Bally, M. B. (2008). Irinophore C: A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy against a Panel of Human Xenograft Tumors. Clin. Cancer Res. 14: 1208-1217 [Abstract] [Full Text]  
• Van Cutsem, E., Verslype, C., Beale, P., Clarke, S., Bugat, R., Rakhit, A., Fettner, S. H., Brennscheidt, U., Feyereislova, A., Delord, J.-P (2008). A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. Ann Oncol 19: 332-339 [Abstract] [Full Text]  
• Lievre, A., Bachet, J.-B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouche, O., Landi, B., Louvet, C., Andre, T., Bibeau, F., Diebold, M.-D., Rougier, P., Ducreux, M., Tomasic, G., Emile, J.-F., Penault-Llorca, F., Laurent-Puig, P. (2008). KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. JCO 26: 374-379 [Abstract] [Full Text]  
• Grothey, A., Hedrick, E. E., Mass, R. D., Sarkar, S., Suzuki, S., Ramanathan, R. K., Hurwitz, H. I., Goldberg, R. M., Sargent, D. J. (2008). Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107. JCO 26: 183-189 [Abstract] [Full Text]  
• Pawlik, T. M., Schulick, R. D., Choti, M. A. (2008). Expanding Criteria for Resectability of Colorectal Liver Metastases. The Oncologist 13: 51-64 [Abstract] [Full Text]  
• Lau, W. Y., Lai, E. C. H. (2007). Salvage Surgery Following Downstaging of Unresectable Hepatocellular Carcinoma A Strategy to Increase Resectability. Ann. Surg. Oncol. 14: 3301-3309 [Abstract] [Full Text]  
• Varghese, S., Burness, M., Xu, H., Beresnev, T., Pingpank, J., Alexander, H. R. (2007). Site-Specific Gene Expression Profiles and Novel Molecular Prognostic Factors in Patients with Lower Gastrointestinal Adenocarcinoma Diffusely Metastatic to Liver or Peritoneum. Ann. Surg. Oncol. 14: 3460-3471 [Abstract] [Full Text]  
• Korita, P. V., Wakai, T., Shirai, Y., Sakata, J., Takizawa, K., Cruz, P. V., Ajioka, Y., Hatakeyama, K. (2007). Intrahepatic Lymphatic Invasion Independently Predicts Poor Survival and Recurrences after Hepatectomy in Patients with Colorectal Carcinoma Liver Metastases. Ann. Surg. Oncol. 14: 3472-3480 [Abstract] [Full Text]  
• Becouarn, Y., Senesse, P., Thezenas, S., Boucher, E., Adenis, A., Cany, L., Jacob, J. H., Cvitkovic, F., Montoto-Grillot, C., Ychou, M. (2007). A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Federation Nationale des Centres de Lutte Contre le Cancer. Ann Oncol 18: 2000-2005 [Abstract] [Full Text]  
• Tang, M. J., Tai, I. T. (2007). A Novel Interaction between Procaspase 8 and SPARC Enhances Apoptosis and Potentiates Chemotherapy Sensitivity in Colorectal Cancers. J. Biol. Chem. 282: 34457-34467 [Abstract] [Full Text]  
• Buyse, M., Burzykowski, T., Carroll, K., Michiels, S., Sargent, D. J., Miller, L. L., Elfring, G. L., Pignon, J.-P., Piedbois, P. (2007). Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer. JCO 25: 5218-5224 [Abstract] [Full Text]  
• Tabernero, J., Van Cutsem, E., Diaz-Rubio, E., Cervantes, A., Humblet, Y., Andre, T., Van Laethem, J.-L., Soulie, P., Casado, E., Verslype, C., Valera, J. S., Tortora, G., Ciardiello, F., Kisker, O., de Gramont, A. (2007). Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer. JCO 25: 5225-5232 [Abstract] [Full Text]  
• Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., Tebbutt, N. C., van Hazel, G., Wierzbicki, R., Langer, C., Moore, M. J. (2007). Cetuximab for the Treatment of Colorectal Cancer. NEJM 357: 2040-2048 [Abstract] [Full Text]  
• Benson, A. B. III (2007). New Approaches to Assessing and Treating Early-Stage Colon and Rectal Cancers: Cooperative Group Strategies for Assessing Optimal Approaches in Early-Stage Disease. Clin. Cancer Res. 13: 6913s-6920s [Abstract] [Full Text]  
• Kornprat, P., Jarnagin, W. R., DeMatteo, R. P., Fong, Y., Blumgart, L. H., D'Angelica, M. (2007). Role of Intraoperative Thermoablation Combined With Resection in the Treatment of Hepatic Metastasis From Colorectal Cancer. Arch Surg 142: 1087-1092 [Abstract] [Full Text]  
• Fuchs, C. S., Marshall, J., Mitchell, E., Wierzbicki, R., Ganju, V., Jeffery, M., Schulz, J., Richards, D., Soufi-Mahjoubi, R., Wang, B., Barrueco, J. (2007). Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study. JCO 25: 4779-4786 [Abstract] [Full Text]  
• Tomlinson, J. S., Jarnagin, W. R., DeMatteo, R. P., Fong, Y., Kornprat, P., Gonen, M., Kemeny, N., Brennan, M. F., Blumgart, L. H., D'Angelica, M. (2007). Actual 10-Year Survival After Resection of Colorectal Liver Metastases Defines Cure. JCO 25: 4575-4580 [Abstract] [Full Text]  
• Tang, P. A., Bentzen, S. M., Chen, E. X., Siu, L. L. (2007). Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line Chemotherapy. JCO 25: 4562-4568 [Abstract] [Full Text]  
• Sorbye, H., Kohne, C.-H., Sargent, D. J., Glimelius, B. (2007). Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: A proposal for standardization of patient characteristic reporting and stratification. Ann Oncol 18: 1666-1672 [Abstract] [Full Text]  
• Yoshino, T., Boku, N., Onozawa, Y., Hironaka, S., Fukutomi, A., Yamaguchi, Y., Hasuike, N., Yamazaki, K., Machida, N., Ono, H. (2007). Efficacy and Safety of an Irinotecan plus Bolus 5-Fluorouracil and L-Leucovorin Regimen for Metastatic Colorectal Cancer in Japanese Patients: Experience in a Single Institution in Japan. Jpn J Clin Oncol 37: 686-691 [Abstract] [Full Text]  
• Zhang, W., Press, O. A., Haiman, C. A., Yang, D. Y., Gordon, M. A., Fazzone, W., El-khoueiry, A., Iqbal, S., Sherrod, A. E., Lurje, G., Lenz, H.-J. (2007). Association of Methylenetetrahydrofolate Reductase Gene Polymorphisms and Sex-Specific Survival in Patients With Metastatic Colon Cancer. JCO 25: 3726-3731 [Abstract] [Full Text]  
• Meropol, N. J. (2007). A Renewed Call for Equipoise. JCO 25: 3392-3394 [Full Text]  
• Saltz, L. B., Niedzwiecki, D., Hollis, D., Goldberg, R. M., Hantel, A., Thomas, J. P., Fields, A. L.A., Mayer, R. J. (2007). Irinotecan Fluorouracil Plus Leucovorin Is Not Superior to Fluorouracil Plus Leucovorin Alone As Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803. JCO 25: 3456-3461 [Abstract] [Full Text]  
• Dy, G. K., Krook, J. E., Green, E. M., Sargent, D. J., Delaunoit, T., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pockaj, B. A., Sticca, R. P., Alberts, S. R., Pitot, H. C. IV, Goldberg, R. M. (2007). Impact of Complete Response to Chemotherapy on Overall Survival in Advanced Colorectal Cancer: Results From Intergroup N9741. JCO 25: 3469-3474 [Abstract] [Full Text]  
• de Gramont, A., Buyse, M., Abrahantes, J. C., Burzykowski, T., Quinaux, E., Cervantes, A., Figer, A., Lledo, G., Flesch, M., Mineur, L., Carola, E., Etienne, P.-L., Rivera, F., Chirivella, I., Perez-Staub, N., Louvet, C., Andre, T., Tabah-Fisch, I., Tournigand, C. (2007). Reintroduction of Oxaliplatin Is Associated With Improved Survival in Advanced Colorectal Cancer. JCO 25: 3224-3229 [Abstract] [Full Text]  
• Haines, I. E. (2007). Questions About the Role of Palifermin in Fluorouracil-Based Therapy for Metastatic Colorectal Cancer. JCO 25: e24-e25 [Full Text]  
• Tomita, N., Fukunaga, M., Okamura, S., Narahara, H., Uedo, N., Ishihara, R., Ishida, H., Furukawa, H., Gotoh, M., Takiuchi, H. (2007). Phase I/II Study of CPT-11 plus UFT in Patients with Advanced/Recurrent Colorectal Cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG): Protocol 0102. Jpn J Clin Oncol 37: 521-527 [Abstract] [Full Text]  
• Welter, S., Jacobs, J., Krbek, T., Krebs, B., Stamatis, G. (2007). Long-Term Survival After Repeated Resection of Pulmonary Metastases From Colorectal Cancer. Ann. Thorac. Surg. 84: 203-210 [Abstract] [Full Text]  
• Pfannschmidt, J., Dienemann, H., Hoffmann, H. (2007). Surgical Resection of Pulmonary Metastases From Colorectal Cancer: A Systematic Review of Published Series. Ann. Thorac. Surg. 84: 324-338 [Abstract] [Full Text]  
• Hiraoka, K., Kimura, T., Logg, C. R., Tai, C.-K., Haga, K., Lawson, G. W., Kasahara, N. (2007). Therapeutic Efficacy of Replication-Competent Retrovirus Vector-Mediated Suicide Gene Therapy in a Multifocal Colorectal Cancer Metastasis Model. Cancer Res. 67: 5345-5353 [Abstract] [Full Text]  
• Mollevi, D. G., Serrano, T., Ginesta, M. M., Valls, J., Torras, J., Navarro, M., Ramos, E., Germa, J. R., Jaurrieta, E., Moreno, V., Figueras, J., Capella, G., Villanueva, A. (2007). Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection. Carcinogenesis 28: 1241-1246 [Abstract] [Full Text]  
• Cote, J.-F., Kirzin, S., Kramar, A., Mosnier, J.-F., Diebold, M.-D., Soubeyran, I., Thirouard, A.-S., Selves, J., Laurent-Puig, P., Ychou, M. (2007). UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan. Clin. Cancer Res. 13: 3269-3275 [Abstract] [Full Text]  
• Fujiwara, Y., Sekine, I., Ohe, Y., Kunitoh, H., Yamamoto, N., Nokihara, H., Simmyo, Y., Fukui, T., Yamada, K., Tamura, T. (2007). Serum Total Bilirubin as a Predictive Factor for Severe Neutropenia in Lung Cancer Patients Treated with Cisplatin and Irinotecan. Jpn J Clin Oncol 0: hym033v1-7 [Abstract] [Full Text]  
• Sanoff, H. K., Bleiberg, H., Goldberg, R. M. (2007). Managing Older Patients With Colorectal Cancer. JCO 25: 1891-1897 [Abstract] [Full Text]  
• Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., Wolf, M., Amado, R. G. (2007). Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer. JCO 25: 1658-1664 [Abstract] [Full Text]  
• Falcone, A., Ricci, S., Brunetti, I., Pfanner, E., Allegrini, G., Barbara, C., Crino, L., Benedetti, G., Evangelista, W., Fanchini, L., Cortesi, E., Picone, V., Vitello, S., Chiara, S., Granetto, C., Porcile, G., Fioretto, L., Orlandini, C., Andreuccetti, M., Masi, G. (2007). Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest. JCO 25: 1670-1676 [Abstract] [Full Text]  
• Ishiguro, M., Iida, S., Uetake, H., Morita, S., Makino, H., Kato, K., Takagi, Y., Enomoto, M., Sugihara, K. (2007). Effect of Combined Therapy With Low-Dose 5-Aza-2'-Deoxycytidine and Irinotecan on Colon Cancer Cell Line HCT-15. Ann. Surg. Oncol. 14: 1752-1762 [Abstract] [Full Text]  
• Wolpin, B. M., Meyerhardt, J. A., Mamon, H. J., Mayer, R. J. (2007). Adjuvant Treatment of Colorectal Cancer. CA Cancer J Clin 57: 168-185 [Abstract] [Full Text]  
• Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., Benson, A. B. III (2007). Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200. JCO 25: 1539-1544 [Abstract] [Full Text]  
• Tanaka, K., Shimada, H., Ueda, M., Matsuo, K., Endo, I., Togo, S. (2007). Long-Term Characteristics of 5-Year Survivors After Liver Resection for Colorectal Metastases. Ann. Surg. Oncol. 14: 1336-1346 [Abstract] [Full Text]  
• Kornprat, P., Jarnagin, W. R., Gonen, M., DeMatteo, R. P., Fong, Y., Blumgart, L. H., D'Angelica, M. (2007). Outcome After Hepatectomy for Multiple (Four or More) Colorectal Metastases in the Era of Effective Chemotherapy. Ann. Surg. Oncol. 14: 1151-1160 [Abstract] [Full Text]  
• Wessner, B., Strasser, E.-M., Koitz, N., Schmuckenschlager, C., Unger-Manhart, N., Roth, E. (2007). Green Tea Polyphenol Administration Partly Ameliorates Chemotherapy-Induced Side Effects in the Small Intestine of Mice. J. Nutr. 137: 634-640 [Abstract] [Full Text]  
• Vredenburgh, J. J., Desjardins, A., Herndon, J. E. II, Dowell, J. M., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Wagner, M., Bigner, D. D., Friedman, A. H., Friedman, H. S. (2007). Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma. Clin. Cancer Res. 13: 1253-1259 [Abstract] [Full Text]  
• D'Angelica, M., Kornprat, P., Gonen, M., Chung, K.-Y., Jarnagin, W. R., DeMatteo, R. P., Fong, Y., Kemeny, N., Blumgart, L. H., Saltz, L. B (2007). Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study. Ann. Surg. Oncol. 14: 759-765 [Abstract] [Full Text]  
• Welter, S., Jacobs, J., Krbek, T., Poettgen, C., Stamatis, G. (2007). Prognostic impact of lymph node involvement in pulmonary metastases from colorectal cancer. Eur. J. Cardiothorac. Surg. 31: 167-172 [Abstract] [Full Text]  
• Rowinsky, E. K., Beeram, M., Hammond, L. A., Schwartz, G., De Bono, J., Forouzesh, B., Chu, Q., Latz, J. E., Hong, S., John, W., Nguyen, B. (2007). A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies. Clin. Cancer Res. 13: 532-539 [Abstract] [Full Text]  
• Meropol, N. J., Schulman, K. A. (2007). Cost of Cancer Care: Issues and Implications. JCO 25: 180-186 [Abstract] [Full Text]  
• Tallman, M. N., Miles, K. K., Kessler, F. K., Nielsen, J. N., Tian, X., Ritter, J. K., Smith, P. C. (2007). The Contribution of Intestinal UDP-Glucuronosyltransferases in Modulating 7-Ethyl-10-hydroxy-camptothecin (SN-38)-Induced Gastrointestinal Toxicity in Rats. J. Pharmacol. Exp. Ther. 320: 29-37 [Abstract] [Full Text]  
• Goldberg, R. M., Rothenberg, M. L., Van Cutsem, E., Benson, A. B. III, Blanke, C. D., Diasio, R. B., Grothey, A., Lenz, H.-J., Meropol, N. J., Ramanathan, R. K., Becerra, C. H. R., Wickham, R., Armstrong, D., Viele, C. (2007). The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer. The Oncologist 12: 38-50 [Abstract] [Full Text]  
• Gholam, D., Giacchetti, S., Brezault-Bonnet, C., Bouchahda, M., Hauteville, D., Adam, R., Ducot, B., Ghemard, O., Kustlinger, F., Jasmin, C., Levi, F. (2006). Chronomodulated Irinotecan, Oxaliplatin, and Leucovorin-Modulated 5-Fluorouracil as Ambulatory Salvage Therapy in Patients with Irinotecan- and Oxaliplatin-Resistant Metastatic Colorectal Cancer. The Oncologist 11: 1072-1080 [Abstract] [Full Text]  
• Koizumi, F., Kitagawa, M., Negishi, T., Onda, T., Matsumoto, S.-i., Hamaguchi, T., Matsumura, Y. (2006). Novel SN-38-Incorporating Polymeric Micelles, NK012, Eradicate Vascular Endothelial Growth Factor-Secreting Bulky Tumors.. Cancer Res. 66: 10048-10056 [Abstract] [Full Text]  
• O'Dwyer, P. J., Catalano, R. B. (2006). Uridine Diphosphate Glucuronosyltransferase (UGT) 1A1 and Irinotecan: Practical Pharmacogenomics Arrives in Cancer Therapy. JCO 24: 4534-4538 [Full Text]  
• Bartlett, D. L., Berlin, J., Lauwers, G. Y., Messersmith, W. A., Petrelli, N. J., Venook, A. P. (2006). Chemotherapy and Regional Therapy of Hepatic Colorectal Metastases: Expert Consensus Statement. Ann. Surg. Oncol. 13: 1284-1292 [Full Text]  
• Minagawa, M., Yamamoto, J., Miwa, S., Sakamoto, Y., Kokudo, N., Kosuge, T., Miyagawa, S.-i., Makuuchi, M. (2006). Selection Criteria for Simultaneous Resection in Patients With Synchronous Liver Metastasis. Arch Surg 141: 1006-1012 [Abstract] [Full Text]  
• Koopman, M, Antonini, N., Douma, J, Wals, J, Honkoop, A., Erdkamp, F., de Jong, R., Rodenburg, C., Vreugdenhil, G, Akkermans-Vogelaar, J., Punt, C. (2006). Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study. Ann Oncol 17: 1523-1528 [Abstract] [Full Text]  
• Schmoll, H.-J., Arnold, D. (2006). Update on Capecitabine in Colorectal Cancer. The Oncologist 11: 1003-1009 [Abstract] [Full Text]  
• Meropol, N. J., Gold, P. J., Diasio, R. B., Andria, M., Dhami, M., Godfrey, T., Kovatich, A. J., Lund, K. A., Mitchell, E., Schwarting, R. (2006). Thymidine Phosphorylase Expression Is Associated With Response to Capecitabine Plus Irinotecan in Patients With Metastatic Colorectal Cancer. JCO 24: 4069-4077 [Abstract] [Full Text]  
• Giantonio, B., Levy, D., O'Dwyer, P., Meropol, N., Catalano, P., Benson, A. III (2006). A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200. Ann Oncol 17: 1399-1403 [Abstract] [Full Text]  
• de Jong, F. A., Kehrer, D. F. S., Mathijssen, R. H. J., Creemers, G.-J., de Bruijn, P., van Schaik, R. H. N., Planting, A. S. Th., van der Gaast, A., Eskens, F. A. L. M., Janssen, J. Th. P., Ruit, J. B., Verweij, J., Sparreboom, A., de Jonge, M. J. A. (2006). Prophylaxis of Irinotecan-Induced Diarrhea with Neomycin and Potential Role for UGT1A1*28 Genotype Screening: A Double-Blind, Randomized, Placebo-Controlled Study. The Oncologist 11: 944-954 [Abstract] [Full Text]  
• Stipa, F., Chessin, D. B., Shia, J., Paty, P. B., Weiser, M., Temple, L. K. F., Minsky, B. D., Wong, W. D., Guillem, J. G. (2006). A Pathologic Complete Response of Rectal Cancer to Preoperative Combined-Modality Therapy Results in Improved Oncological Outcome Compared With Those Who Achieve No Downstaging on the Basis of Preoperative Endorectal Ultrasonography. Ann. Surg. Oncol. 13: 1047-1053 [Abstract] [Full Text]  
• Masi, G., Marcucci, L., Loupakis, F., Cerri, E., Barbara, C., Bursi, S., Allegrini, G., Brunetti, I. M., Murr, R., Ricci, S., Cupini, S., Andreuccetti, M., Falcone, A. (2006). First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. Ann Oncol 17: 1249-1254 [Abstract] [Full Text]  
• Van Cutsem, E. (2006). Progress With Biological Agents in Metastatic Colorectal Cancer Leads to Many Challenges. JCO 24: 3325-3327 [Full Text]  
• Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., Alberts, S. (2006). Randomized Controlled Trial of Reduced-Dose Bolus Fluorouracil Plus Leucovorin and Irinotecan or Infused Fluorouracil Plus Leucovorin and Oxaliplatin in Patients With Previously Untreated Metastatic Colorectal Cancer: A North American Intergroup Trial. JCO 24: 3347-3353 [Abstract] [Full Text]  
• Chen, H. X., Mooney, M., Boron, M., Vena, D., Mosby, K., Grochow, L., Jaffe, C., Rubinstein, L., Zwiebel, J., Kaplan, R. S. (2006). Phase II Multicenter Trial of Bevacizumab Plus Fluorouracil and Leucovorin in Patients With Advanced Refractory Colorectal Cancer: An NCI Treatment Referral Center Trial TRC-0301. JCO 24: 3354-3360 [Abstract] [Full Text]  
• Girard, H., Villeneuve, L., Court, M. H., Fortier, L.-C., Caron, P., Hao, Q., von Moltke, L. L., Greenblatt, D. J., Guillemette, C. (2006). THE NOVEL UGT1A9 INTRONIC I399 POLYMORPHISM APPEARS AS A PREDICTOR OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN GLUCURONIDATION LEVELS IN THE LIVER. Drug Metab. Dispos. 34: 1220-1228 [Abstract] [Full Text]  
• Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., Demetri, G., Desch, C. E., Pizzo, P. A., Schiffer, C. A., Schwartzberg, L., Somerfield, M. R., Somlo, G., Wade, J. C., Wade, J. L., Winn, R. J., Wozniak, A. J., Wolff, A. C. (2006). 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. JCO 24: 3187-3205 [Abstract] [Full Text]  
• Dumez, H., Awada, A., Piccart, M., Assadourian, S., Semiond, D., Guetens, G., de Boeck, G., Maes, R. A. A., de Bruijn, E. A., van Oosterom, A. (2006). A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours. Ann Oncol 17: 1158-1165 [Abstract] [Full Text]  
• Kuppens, I. E.L.M., Dansin, E., Boot, H., Feger, C., Assadourian, S., Bonneterre, M.-E., Beijnen, J. H., Schellens, J. H.M., Bonneterre, J. (2006). Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors.. Clin. Cancer Res. 12: 3774-3781 [Abstract] [Full Text]  
• Han, J.-Y., Lim, H.-S., Shin, E. S., Yoo, Y.-K., Park, Y. H., Lee, J.-E., Jang, I.-J., Ho Lee, D., Soo Lee, J. (2006). Comprehensive Analysis of UGT1A Polymorphisms Predictive for Pharmacokinetics and Treatment Outcome in Patients With Non-Small-Cell Lung Cancer Treated With Irinotecan and Cisplatin. JCO 24: 2237-2244 [Abstract] [Full Text]  
• Innocenti, F., Vokes, E. E., Ratain, M. J. (2006). Irinogenetics: What Is the Right Star?. JCO 24: 2221-2224 [Full Text]  
• Wei, A. C., Greig, P. D., Grant, D., Taylor, B., Langer, B., Gallinger, S. (2006). Survival After Hepatic Resection for Colorectal Metastases: A 10-Year Experience. Ann. Surg. Oncol. 13: 668-676 [Abstract] [Full Text]